GRM3 and central nervous system cancer: Ciceroni et al., have demonstrated that glioma-initiating CD133-positive stem cells express the metabotropic glutamate receptor 3 (GRM3/mGluR3) and that pharmacologic blockade of mGluR3 results in committed differentiation into benign astrocyte-like cells.